The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Open accessAbstract
Ketamine, a racemic mixture of (S)-ketamine and (R)-ketamine enantiomers, has been used as an anesthetic, analgesic and more recently, as an antidepressant. However, ketamine has known abuse liability (the tendency of a drug to be used in non-medical situations due to its psychoactive effects), which raises concerns for its therapeutic use. (S)-ketamine was recently approved by the United States' FDA for treatment-resistant depression. Recent studies showed that (R)-ketamine has greater efficacy than (S)-ketamine in preclinical models of depression, but its clinical antidepressant efficacy has not been established. The behavioral effects of racemic ketamine have been studied extensively in preclinical models predictive of abuse liability in humans (self-administration and conditioned place preference [CPP]). In contrast, the behavioral effects of each enantiomer in these models are unknown. We show here that in the intravenous drug self-administration model, the gold standard procedure to assess potential abuse liability of drugs in humans, rats self-administered (S)-ketamine but not (R)-ketamine. Subanesthetic, antidepressant-like doses of (S)-ketamine, but not of (R)-ketamine, induced locomotor activity (in an opioid receptor-dependent manner), induced psychomotor sensitization, induced CPP in mice, and selectively increased metabolic activity and dopamine tone in medial prefrontal cortex (mPFC) of rats. Pharmacological screening across thousands of human proteins and at biological targets known to interact with ketamine yielded divergent binding and functional enantiomer profiles, including selective mu and kappa opioid receptor activation by (S)-ketamine in mPFC. Our results demonstrate divergence in the pharmacological, functional, and behavioral effects of ketamine enantiomers, and suggest that racemic ketamine's abuse liability in humans is primarily due to the pharmacological effects of its (S)-enantiomer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, similar range of affinity values at μ and κ opioid receptors were recently reported for (S)-ketamine (μ: Ki = 7 μM and κ: Ki = 19 μM) and (R)-ketamine (μ: Ki = 14 μM and κ: Ki = 40 μM) (Bonaventura et al.,”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, this study’s main findings rely on computational analysis and the predicted affinity and G protein recruitment values it reports are not consistent with several prior publications (Bonaventura et al., 2021; Hirota et al., 1999; Nemeth et al., 2010).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“conditioned lever responding for (S)-ketamine is rapidly extinguished with fewer than 10 responses over three hours on the first extinction training day”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, (S) and (R)-ketamine have agonist properties at μ and κ opioid receptors, an interaction which may be necessary for their antidepressant effects (Bonaventura et al., 2021).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“preclinical evidence suggests that ketamine therapy may be associated with certain risks, such as increasing drug-dependence-related behaviors like self-administration, conditioned place preference, hyperlocomotion, and prepulse inhibition deficits [155-157]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [155]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinically, (R)-ketamine does not induce conditioned place preference, deficits in prepulse inhibition, or hyperlocomotion [155-157]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [155]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“(S)-ketamine induces conditioned place preference in mice and conditioned operant lever responding for an infusion in rats whereas (R)-ketamine largely does not”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“this study showed that (S)-ketamine acted as a partial G protein signaling agonist at μ opioid receptors (EC50 = 9 μM, Emax = 48%) and as a full agonist at κ opioid receptors (EC50 = 16 μM, Emax = 84 %)”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, neither enantiomer activated ß-arrestin.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“whereas (R)-ketamine acted as a weak partial agonist at both μ opioid receptors (EC50 = 34 μM, Emax = 39 %) and κ opioid receptors (EC50 > 100 μM, Emax < 50%).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Intriguingly, (R) and (S)-ketamine appear to have agonist properties at μ and κ opioid receptors, with (S)-ketamine having a higher affinity”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Bonaventura et al., 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
A Simple Practice Guide for Dose Conversion between Animals and Human
Nair, A., & Jacob, S. (2016) · Journal of Basic and Clinical Pharmacy · doi:10.4103/0976-0105.177703 · Cited by 6,174
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationA psychomotor stimulant theory of addiction.
Wise, R. A., & Bozarth, M. A. (1987) · Psychological Review · doi:10.1037/0033-295x.94.4.469 · Cited by 2,747
Kalivas, P., & Stewart, J. (1991) · Brain research. Brain research reviews · doi:10.1016/0165-0173(91)90007-u · Cited by 2,087
Wise, R. A., & Rompre, P.-P. (1989) · Annual Review of Psychology · doi:10.1146/annurev.ps.40.020189.001203 · Cited by 1,968
Opioids excite dopamine neurons by hyperpolarization of local interneurons
Johnson, S., & North, R. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-02-00483.1992 · Cited by 1,637
Richardson, N. R., & Roberts, D. C. S. (1996) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(95)00153-0 · Cited by 1,373
Conditioned place preference: what does it add to our preclinical understanding of drug reward?
Bardo, M. T., & Bevins, R. A. (2000) · Psychopharmacology · doi:10.1007/s002130000569 · Cited by 1,274
Cited by
Sorted by citations
Brain–gut–microbiota axis in depression: A historical overview and future directions
Chang, L., Wei, Y., & Hashimoto, K. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.004 · Cited by 407
Microglial ERK-NRBP1-CREB-BDNF Signaling in Sustained Antidepressant Actions of (R)-Ketamine
Yao, W., Cao, Q., Luo, S., He, L., Yang, C., Chen, J., Qi, Q., Hashimoto, K., & Zhang, J.-C. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01377-7 · Cited by 216
Qiu, D., Wang, X., Yang, J.-J., Chen, S., Yue, C., Hashimoto, K., & Yang, J. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.44514 · Cited by 195
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Self-citationKetamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
Self-citationA Look at the Importance of Chirality in Drug Activity: Some Significative Examples
Ceramella, J., Iacopetta, D., Franchini, A., Luca, M. D., Saturnino, C., Andreu, I., Sinicropi, M. S., & Catalano, A. A. (2022) · Applied Sciences · doi:10.3390/app122110909 · Cited by 158
The antidepressant actions of ketamine and its enantiomers
Johnston, J. N., Henter, I. D., & Zarate, C. A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108431 · Cited by 112
Self-citationKetamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Self-citationThe opioid system in depression
Jelen, L. A., Stone, J. M., Young, A. H., & Mehta, M. A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104800 · Cited by 108
Randomized trial of ketamine masked by surgical anesthesia in patients with depression
Lii, T. R., Smith, A. E., Flohr, J. R., Okada, R. L., Nyongesa, C. A., Cianfichi, L. J., Hack, L. M., Schatzberg, A. F., & Heifets, B. D. (2023) · Nature Mental Health · doi:10.1038/s44220-023-00140-x · Cited by 131
Arketamine, a new rapid-acting antidepressant: A historical review and future directions
Zhang, J.-C., Yao, W., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109219 · Cited by 93
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
The abuse liability of ketamine: A scoping review of preclinical and clinical studies
Le, T. T., Cordero, I. P., Jawad, M. Y., Swainson, J., Vincenzo, J. D. D., Jaberi, S., Phan, L., Lui, L. M. W., Ho, R., Rosenblat, J. D., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.04.035 · Cited by 84
Fava, M., Stahl, S., Pani, L., De Martin, S., Pappagallo, M., Guidetti, C., Alimonti, A., Bettini, E., Mangano, R. M., Wessel, T., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21020197 · Cited by 83
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 92
Krystal, J. H., Kaye, A. P., Jefferson, S., Girgenti, M. J., Wilkinson, S. T., Sanacora, G., & Esterlis, I. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305772120 · Cited by 83
Bahji, A., Zarate, C. A., & Vázquez, G. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047928 · Cited by 78
Self-citationTreatment-resistant depression: molecular mechanisms and management
Kajumba, M. M., Kakooza‐Mwesige, A., Nakasujja, N., Attix, D. K., & Canli, T. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00205-y · Cited by 93
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 73
Self-citationKetamine and its metabolites: Potential as novel treatments for depression
Zhang, K., Yao, Y., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109305 · Cited by 69
Tian, F., Lewis, L. D., Zhou, D. W., Balanza, G. A., Paulk, A. C., Zelmann, R., Peled, N., Soper, D. J., Mercado, L. A. S. C., Peterfreund, R. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37463-3 · Cited by 66
Chen, Y., Guo, Y., Wu, H., Tang, Y.-J., Sooranna, S. R., Zhang, L., Chen, T., Xie, X., Qiu, L., & Wu, X. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.0953 · Cited by 66
Wang, X., Chang, L., Wan, X., Tan, Y., Qu, Y., Shan, J., Yang, Y. H., Ma, L., & Hashimoto, K. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105635 · Cited by 67
Leal, G. C., Souza-Marques, B., Mello, R. P., Bandeira, I. D., Caliman-Fontes, A. T., Carneiro, B. A., Faria-Guimarães, D., Guerreiro-Costa, L. N. F., Jesus-Nunes, A. P., Silva, S. S., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.151 · Cited by 62
(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: Beyond depression
Wang, X., Yang, J., & Hashimoto, K. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104762 · Cited by 62
Remodeling of microbiota gut-brain axis using psychobiotics in depression
Palepu, M. S. K., & Dandekar, M. P. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175171 · Cited by 62
Liu, Q.-R., Zong, Q.-K., Ding, L., Dai, H.-Y., Sun, Y., Dong, Y.-Y., Ren, Z.-Y., Hashimoto, K., & Yang, J. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.07.103 · Cited by 60
Levinstein, M. R., Budinich, R. C., Bonaventura, J., Schatzberg, A. F., Zarate, C. A., & Michaelides, M. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240378 · Cited by 58
Self-citationHashimoto, K. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01770-7 · Cited by 58
Muscat, S.-A., Hartelius, G., Crouch, C., & Morin, K. W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.710338 · Cited by 59
Levinstein, M. R., Carlton, M. L., Ianni, T. D., Ventriglia, E. N., Rizzo, A., Gomez, J. L., Budinich, R. C., Shaham, Y., Airan, R. D., Zarate, C. A., et al. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.12.019 · Cited by 51
Self-citationUncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant
Xu, S., Yao, X., Li, B., Cui, R., Zhu, C., Wang, Y., & Yang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.740996 · Cited by 53
Ma, L., Zhang, J., Fujita, Y., Qu, Y., Shan, J., Wan, X., Wang, X., Ishima, T., Kobayashi, K., Wang, L., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01803-6 · Cited by 52
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Brown, K. A., & Gould, T. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02397-1 · Cited by 49
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
Bonaventura, J., Gomez, J. L., Carlton, M. L., Lam, S., Sánchez‐Soto, M., Morris, P. J., Moaddel, R., Kang, H. J., Zanos, P., Gould, T. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01673-w · Cited by 47
Self-citationKetamine: anesthetic, psychotomimetic, antidepressant, or anthelmintic?
Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01587-7 · Cited by 45
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder
Dean, R. L., Marquardt, T., Hurducas, C., Spyridi, S., Barnes, A., Smith, R. P., Cowen, P. J., McShane, R. H., Hawton, K. E., Malhi, G. S., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011611.pub3 · Cited by 43
Jiang, C. S., Dileone, R., Pittenger, C., & Duman, R. S. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02796-0 · Cited by 45
Ma, L., Wang, L., Chang, L., Shan, J., Qu, Y., Wang, X., Wan, X., Fujita, Y., & Hashimoto, K. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02192-6 · Cited by 43
Arketamine for cognitive impairment in psychiatric disorders
Hashimoto, K. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01570-5 · Cited by 42
Ma, L., Wang, L., Chang, L., Shan, J., Qu, Y., Wang, X., Fujita, Y., & Hashimoto, K. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109250 · Cited by 42
Qu, Y., Chang, L., Ma, L., Wan, X., & Hashimoto, K. (2022) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2022.173500 · Cited by 44
In vivo photopharmacology with light-activated opioid drugs
McClain, S. P., Ma, X., Johnson, D. A., Johnson, C. A., Layden, A. E., Yung, J. C., Lubejko, S. T., Livrizzi, G., He, X. J., Zhou, J., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.09.017 · Cited by 43
Self-citationMurayama, R., Cai, Y., Nakamura, H., & Hashimoto, K. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106209 · Cited by 44
Jelen, L. A., Lythgoe, D. J., Stone, J. M., Young, A. H., & Mehta, M. A. (2025) · Nature Medicine · doi:10.1038/s41591-025-03800-w · Cited by 41
Hashimoto, K., Zhao, M., Zhu, T., Wang, X., & Yang, J. (2024) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2024.07.001 · Cited by 38
Purohit, M. P., Yu, B. J., Roy, K. S., Xiang, Y., Ewbank, S. N., Azadian, M. M., Hart, A. R., Muwanga, G. P. B., Martinez, P. J., Wang, J. B., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01990-5 · Cited by 39
Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine
Mathai, D. S., Nayak, S. M., Yaden, D. B., & Garcia‐Romeu, A. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06324-8 · Cited by 37
Artin, H., Bentley, S., Mehaffey, E., Liu, F. X., Sojourner, K., Bismark, A. W., Printz, D., Lee, E., Martis, B., Peralta, S. D., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101439 · Cited by 38
Gan, S.-L., Long, Y.-Q., Wang, Q., Feng, C.-D., Lai, C.-X., Liu, C., Ding, Y.-Y., Liu, H., Peng, K., & Ji, F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1128406 · Cited by 37
Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats
Ianni, T. D., Ewbank, S. N., Levinstein, M. R., Azadian, M. M., Budinich, R. C., Michaelides, M., & Airan, R. D. (2024) · Nature Communications · doi:10.1038/s41467-024-45157-7 · Cited by 33
Self-citationScotton, E., Antqueviezc, B., Vasconcelos, M., Dalpiaz, G., Géa, L. P., Goularte, J. F., Colombo, R., & Rosa, A. R. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114963 · Cited by 37
A bibliometric analysis of research on (R)-ketamine from 2002 to 2021
He, T., Wang, D., Wu, Z., Huang, C., Xu, X., Xu, X., Liu, C., Hashimoto, K., & Yang, C. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109207 · Cited by 35
Limoges, A., Yarur, H. E., & Tejeda, H. A. (2022) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2022.963691 · Cited by 35
Expanding the Role of Chiral Drugs and Chiral Nanomaterials as a Potential Therapeutic Tool
Satapathy, S., Kumar, S., Kurmi, B. D., Gupta, G. D., & Patel, P. (2024) · Chirality · doi:10.1002/chir.23698 · Cited by 34
Ma, C.-B., Zhang, C.-Y., Gou, C.-L., Liang, Z., Zhang, J., Xing, F., Yuan, J., Wei, X., Zhang, Y., & Wang, Z. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s477342 · Cited by 34
Wen, Y., Mao, M., Wang, X., Xu, C., Shi, X., Li, P., Tian, Z., Jiang, M., Yuan, H., & Feng, S. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115765 · Cited by 35
Wang, Y. Y., Jiang, R., Wu, Z., Zhou, L., Xu, J., Huang, C., Yang, L., Zhu, B., Yan, E., Liu, C., et al. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173226 · Cited by 31
Popik, P., Hogendorf, A. S., Bugno, R., Khoo, S. Y., Zajdel, P., Malikowska‐Racia, N., Nikiforuk, A., & Gołębiowska, J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06020-5 · Cited by 31
Esmethadone-HCl (REL-1017): a promising rapid antidepressant
D, M. F. M., Stahl, S. M., Martin, S. D., Mattarei, A., Bettini, E., Comai, S., Alimonti, A., Bifari, F., Pani, L., Folli, F. B., et al. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01571-4 · Cited by 32
(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders
Shafique, H. S., Demers, J. C., Biesiada, J., Golani, L. K., Cerne, R., Smith, J. L., Szostak, M., & Witkin, J. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126804 · Cited by 31
Feng, M., Shi, G., Cui, W., Zhang, N., Xie, Q., & Zhang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1034236 · Cited by 30
Levinstein, M. R., de Oliveira, P. A., Casajuana-Martín, N., Quiroz, C., Budinich, R. C., Rais, R., Rea, W. P., Ventriglia, E. N., Llopart, N., Casadó-Anguera, V., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02353-z · Cited by 27
Self-citationKetamine rescues anhedonia by cell-type- and input-specific adaptations in the nucleus accumbens
Lucantonio, F., Roeglin, J., Li, S., Lu, J., Shi, A., Czerpaniak, K., Fiocchi, F. R., Bontempi, L., Shields, B. C., Zarate, C. A., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.02.021 · Cited by 33
Self-citationZhang, J., Ma, L., Hashimoto, Y., Wan, X., Shan, J., Qu, Y., & Hashimoto, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119882 · Cited by 30
Wulf, H. A., Browne, C. A., Zarate, C. A., & Lucki, I. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06118-4 · Cited by 27
Self-citationMa, L., Wang, L., Qu, Y., Wan, X., & Hashimoto, K. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02564-6 · Cited by 26
Randomized Trial of Ketamine Masked by Surgical Anesthesia in Depressed PatientsPreprint
Lii, T. R., Smith, A. E., Flohr, J. R., Okada, R. L., Nyongesa, C. A., Cianfichi, L. J., Hack, L. M., Schatzberg, A. F., & Heifets, B. D. (2023) · medRxiv · doi:10.1101/2023.04.28.23289210 · Cited by 26
An integrative view on the cell-type-specific mechanisms of ketamine's antidepressant actions
Lewis, V., Rurak, G. M., Salmaso, N., & Aguilar‐Valles, A. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2023.12.004 · Cited by 31
Chang, L., Wei, Y., Qu, Y., Zhao, M., Zhou, X., Long, Y., & Hashimoto, K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106573 · Cited by 25
(R)-ketamine ameliorates the progression of experimental autoimmune encephalomyelitis in mice
Wang, X., Chang, L., Tan, Y., Qu, Y., Shan, J., & Hashimoto, K. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.10.013 · Cited by 25
Reyes-Lizaola, S., Luna-Zarate, U., Tendilla‐Beltrán, H., Morales‐Medina, J. C., & Flores, G. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110876 · Cited by 26
Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors
Gomes, I., Gupta, A., Margolis, E. B., Fricker, L. D., & Devi, L. A. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000947 · Cited by 29
Yokoyama, R., Ago, Y., Igarashi, H., Higuchi, M., Tanuma, M., Shimazaki, Y., Kawai, T., Seiriki, K., Hayashida, M., Yamaguchi, S., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02419-6 · Cited by 26
Converging circuits between pain and depression: the ventral tegmental area as a therapeutic hub
Flores-García, M., Rizzo, A., Garçon-Poca, M. Z., Fernández‐Dueñas, V., & Bonaventura, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1278023 · Cited by 25
Self-citationXu, D., Liu, G., Zhao, M., Wan, X., Qu, Y., Murayama, R., & Hashimoto, K. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.222 · Cited by 23
Tan, Y., Fujita, Y., Pu, Y., Chang, L., Qu, Y., Wang, X., & Hashimoto, K. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01365-6 · Cited by 21
Adžić, M., Lukić, I., Mitić, M., Glavonic, E., Dragicevic-Curic, N., & Ivković, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121803 · Cited by 22
Ingrosso, G., Cleare, A. J., & Juruena, M. F. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303597 · Cited by 21
Rizzo, A., Garçon-Poca, M. Z., Essmann, A., Souza, A. J., Michaelides, M., Ciruela, F., & Bonaventura, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02931-3 · Cited by 24
Self-citationLewis, V., Rodrigue, B., Arsenault, E., Zhang, M., Taghavi‐Abkuh, F., Silva, W. C. C., Myers, M., Matta‐Camacho, E., & Aguilar‐Valles, A. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15652 · Cited by 21
Yücel, N. T., Evren, A. E., Kandemir, Ü., & Can, Ö. D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221095528 · Cited by 19
Schatzberg, A. F. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20220434 · Cited by 19
Chen, B. K., & Denny, C. A. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109345 · Cited by 19
Liu, G., Ma, L., Qu, Y., Wan, X., Xu, D., Zhao, M., Murayama, R., & Hashimoto, K. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173659 · Cited by 18
Esketamine in depression: putative biomarkers from clinical research
Johnston, J. N., Zarate, C. A., & Kvarta, M. D. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01865-1 · Cited by 19
Self-citationThe role of NMDARs in the anesthetic and antidepressant effects of ketamine
Zhou, L., & Duan, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14464 · Cited by 17
D, M. F. M., Stahl, S. M., Pani, L., Martin, S. D., Cutler, A. J., Maletic, V., Gorodetzky, C. W., Vocci, F. J., Sapienza, F. L., Kosten, T. R., et al. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.24m15265 · Cited by 17
Ketamine and Esketamine for Depression in Daily Practice
Singh, B. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001898 · Cited by 17
Can ketamine be a safe option for treatment-resistant bipolar depression?
Singh, B., Voort, J. L. V., Frye, M. A., & Kung, S. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2045272 · Cited by 17
Henningfield, J. E., Gauvin, D. V., Bifari, F., Fant, R. V., Shram, M. J., Buchhalter, A. R., Ashworth, J., Lanier, R. K., Pappagallo, M., Inturrisi, C. E., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-15055-3 · Cited by 16
Johnston, J. N., Allen, J., Shkolnikov, I., Sánchez-Lafuente, C. L., Reive, B. S., Scheil, K., Liang, S., Christie, B. R., Kalynchuk, L. E., & Caruncho, H. J. (2023) · eNeuro · doi:10.1523/eneuro.0106-23.2023 · Cited by 18
Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use Disorders
Onisiforou, A., Michael, A., Apostolakis, M., Mammadov, E., Mitka, A., Kalatta, M. A., Koumas, M., Georgiou, A. N., Chatzittofis, A., Panayiotou, G., et al. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.09.008 · Cited by 16
Self-citationParental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality
Mathai, D. S., McCathern, A. G., Guzick, A. G., Schneider, S. C., Weinzimmer, S. A., Cepeda, S. L., Garcia‐Romeu, A., & Storch, E. A. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2021.0078 · Cited by 18
Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Ruhé, H. G., Rot, M. A. H., Kamphuis, J., de Boer, M. K., & Schoevers, R. A. (2021) · BJPsych Open · doi:10.1192/bjo.2021.1059 · Cited by 17
Microglial BDNF modulates arketamine’s antidepressant-like effects through cortico-accumbal pathways
He, L., Wang, X., Luo, S., Jiang, N., Yan, Y., Xie, M., Chen, Y., Yang, C., Yao, W., Hashimoto, K., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv5986 · Cited by 17
Xiao, H., Zhang, Q., Zhong, P., Tang, G., Tao, L., Huang, Z., Guo, D., Liao, Y., Peng, Y., Wu, Z., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00381 · Cited by 15
Flynn, L. T., & Gao, W. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02235-4 · Cited by 16
Chen, M., Jin, J., Bi, H., Zhang, Y., Sun, M., Li, X., & Wang, Y. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104502 · Cited by 14
Metadata
- Authors
- Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., Sibley, D. R., Shaham, Y., Zarate, C. A., & Michaelides, M.
- Affiliations
- National Institutes of Health (US)
- National Institute on Drug Abuse (US)
- National Center for Advancing Translational Sciences (US)
- National Institute of Neurological Disorders and Stroke (US)
- National Institute of Mental Health (US)
- Corresponding author
- Bonaventura, Jordi
- Michaelides, Michael
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2021-04-15
- Volume
- 26
- Issue
- 11
- Pages
- 6704-6722
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC8517038
- OpenAlex
- W3156594315
- Cited by
- 271
- References
- 86
- Citations by year
- 2026: 35 · 2025: 46 · 2024: 64 · 2023: 56 · 2022: 53 · 2021: 17
- FWCI
- 27.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA000069)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- ketamine, enantiomers, esketamine, (R)-ketamine, abuse liability, self-administration, conditioned place preference, locomotor activity, locomotor sensitization, medial prefrontal cortex, dopamine, opioid receptors, mu-opioid receptor, kappa opioid receptor, antidepressant efficacy, treatment-resistant depression
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Stereoisomerism, Mice, Rats, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
